What is the Beta Drugs PE ratio today?
Beta Drugs' PE ratio is 37.5 at the 30 October 2026 close (₹1,798.40 a share): a market capitalisation of ₹2,000 crore divided by consolidated net profit of ₹53.3 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹41.5 crore) it is 48.2.
What is the Beta Drugs net worth?
Beta Drugs' net worth — shareholders' equity in its consolidated balance sheet — was ₹438 crore on 30 September 2026. Its market value is a different figure: a market capitalisation of ₹2,000 crore at the 30 October 2026 close.
What is the Beta Drugs promoter holding?
Promoters held 58.91% of Beta Drugs on 30 September 2026, down 0.19 percentage points from 59.10% the previous quarter and down 7.82 percentage points from 66.73% a year earlier, according to the shareholding pattern filed with NSE.
What is the Beta Drugs PB ratio (price to book value)?
Beta Drugs' price-to-book (PB) ratio is 4.57 at the 30 October 2026 close: a market capitalisation of ₹2,000 crore divided by shareholders' equity (book value) of ₹438 crore on 30 September 2026. That is a book value of ₹393.58 per share against a share price of ₹1,798.40.
What is the Beta Drugs shareholding pattern?
On 30 September 2026, Beta Drugs' shares were held by promoters 58.91%, foreign portfolio investors (FII/FPI) 1.37%, domestic institutions (DII) 6.45% and retail and other non-institutional investors 33.27%. Over the year, FII holding was up 0.47 percentage points from 0.90% and DII holding was up 6.16 percentage points from 0.29%.
What are the Beta Drugs latest quarterly results?
Beta Drugs' latest results are for Q2 FY27 (July–September 2026), filed on 22 October 2026: consolidated net profit ₹19.3 crore, down 19.4% from ₹23.9 crore in Q2 FY26; revenue from operations ₹137 crore, down 32.5% year on year.
What is the Beta Drugs market cap?
Beta Drugs' market capitalisation was ₹2,000 crore at the 30 October 2026 close: 1.11 crore shares at ₹1,798.40 each.
Is Beta Drugs debt free?
No. Beta Drugs had borrowings of ₹48.7 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.10. Its cash and current investments were ₹104 crore, so it held net cash of ₹55.1 crore.
What is the Beta Drugs debt to equity ratio?
Beta Drugs' debt-to-equity ratio was 0.10 on 30 September 2026: borrowings of ₹48.7 crore against total equity of ₹475 crore.
What is the Beta Drugs book value per share?
Beta Drugs' book value per share was ₹393.58 on 30 September 2026: shareholders' equity of ₹438 crore divided by the 1.11 crore shares in issue. The share price at the 30 October 2026 close was ₹1,798.40.
What is the Beta Drugs free cash flow?
In FY26, Beta Drugs generated ₹37.3 crore of cash from operations and spent ₹53.5 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹16.2 crore. In FY25 it was −₹5.3 crore.
When are the Beta Drugs next results?
Beta Drugs has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
What is the Beta Drugs EPS?
Beta Drugs' basic earnings per share (EPS) were ₹40.92 in FY26, against ₹42.02 in FY25.
What is the Beta Drugs revenue and profit in FY26?
In FY26 (April 2025–March 2026), Beta Drugs' consolidated net profit was ₹41.5 crore, down 2.2% from ₹42.4 crore in FY25, on revenue from operations of ₹385 crore (up 6.2%).
How does Beta Drugs compare with its peers?
On FY26 consolidated figures, against Thejo Engineering and Macpower CNC Machines: Beta Drugs' operating margin of 15.2% is the highest of the three (Thejo Engineering 10.3%, Macpower CNC Machines 14.0%; peer average 12.1%).
How does the Beta Drugs PE ratio compare with its peers?
At the 30 October 2026 closing prices, on FY26 net profit, Beta Drugs' PE ratio is 48.2, the second highest of the three: Thejo Engineering 44.2 and Macpower CNC Machines 57.5, a peer average of 50.9. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Beta Drugs vs Thejo Engineering: how do they compare?
In FY26, Beta Drugs earned net profit of ₹41.5 crore on revenue of ₹385 crore, against ₹49.3 crore on ₹632 crore for Thejo Engineering. Beta Drugs' operating margin was 15.2% (Thejo Engineering 10.3%). At the 30 October 2026 close, Beta Drugs' market capitalisation was ₹2,000 crore against ₹2,179 crore for Thejo Engineering, and its PE ratio on FY26 profit 48.2 against 44.2.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
